ADAR1 Capital Management, LLC, 10% Owner at NextCure, Inc. (NXTC), bought 17,608 shares at $5.00 ($88K) on 2026-07-27, disclosed to the SEC on 2026-07-29.
ADAR1 Capital Management, LLC purchased 7,798 shares of NextCure (NXTC) for $38,985.32 on July 27, 2026, marking the largest insider purchase in the company's history. This significant buyback by a 10% holder suggests confidence in the stock's recovery potential following a sharp decline.
NXTC is currently trading at $5.055, representing a 14.89% gain over the last 5 days and a massive 180.83% increase over the past 30 days. Despite this recent rally, the stock remains significantly depressed, sitting 67.88% below its 52-week high of $15.74.
NextCure is approaching its next earnings report on August 4, 2026, which will be a key test of the recent momentum. Additionally, analysts have set a price target implying a potential upside of 107.88% as of November 11, 2025, providing a clear upside target for the trade.
The stock remains highly volatile with a beta of 1.272, and it currently carries a short interest of 3.09% of the float, indicating some skepticism among traders. Furthermore, the company is unprofitable with a negative forward P/E of -1.25, which poses a fundamental risk to the valuation.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.00 | 7,798 | $39K | 44.4% |
| 2 | $4.95 | 6,400 | $32K | 36.1% |
| 3 | $5.00 | 1,600 | $8K | 9.1% |
| 4 | $5.00 | 1,810 | $9K | 10.3% |
| Total | $4.98 avg | 17,608 | $88K | 100% |
| Filing → |
| INM | BUY | 2026-10-05 | $57K | — | Filing → |
| INM | BUY | 2026-09-16 | $118K | — | Filing → |
| TENX | BUY | 2026-09-08 | $1.6M | — | Filing → |